A Phase 3 interventional study of triamcinolone acetonide and placebo in Rhinitis, sponsored by Sanofi. Terminated at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-12-07.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Rhinitis with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Rhinitis · France.
Among the 13 studies in Rhinitis with a site in France, this one is the only one that started in 2006, is one of 2 in phase 3, and was the 1st registered.
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
Browse Rhinitis studies →3 of the 13 studies in Rhinitis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–70
University Hospital, Caen · Sites in France
Laboratoires Elerte · Sites in France
Ages 8+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 80 across 187 interventional studies indexed under Rhinitis.
Median enrollment 180 across the 8 interventional studies, 356 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 6 studies filed under Rhinitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Rhinitis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07383493University Hospital, Clermont-FerrandRhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis | 2027-03 |
| NCT07620522Laboratoires ElerteObservational Study of RHINOSEDAL in Acute Nasal Obstruction | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Rhinitis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the superiority of the clinical efficacy of 12 weeks' treatment with Nasacort versus placebo in adult patients presenting with Chronic Non Allergic and Non Infectious Rhinitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: triamcinolone acetonide
Drug: placebo
220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
a double spray into each nostril once daily
Mean global score obtained on the basis of 5 evaluations : nasal obstruction, rhinorrhea, disturbed sense of smell, sneezing, facial heaviness.
Time frame: 7 days prior to each visit
list of undesirable events
Time frame: during the treatment period
The record gives a start of Apr 2006 and a primary completion of Apr 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide